Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Asparaginase Erwinia chrysanthemi · Rylaze, JZP-458

Recombinant protein · Kills target cells, directed at L-asparagine · developed by Jazz Pharms

Approved FDA, Jun 2021

JAZZ Developer

1 Registered trials

What is Asparaginase Erwinia chrysanthemi?

Rylaze is a recombinant asparaginase enzyme derived from Erwinia chrysanthemi that catalyzes conversion of L-asparagine to aspartic acid and ammonia. It depletes asparagine in leukemic cells, blocking protein synthesis and causing cell death in patients with acute lymphoblastic leukemia or lymphoblastic lymphoma who are hypersensitive to E. coli-derived asparaginase.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Rylaze, JZP-458, PF743, Crisantaspase, Crisantaspase Biobetter JZP-458, Crisantaspasum, Enrylaze
Drug type: Recombinant protein
Targets: L-asparagine
Mechanism: Kills target cells, directed at L-asparagine
Pathways: protein synthesis, cell proliferation
Therapy area: Oncology
Developer: Jazz Pharms (JAZZ)
FDA status: Approved as Rylaze (June 30, 2021), BLA761179 · FDA label
UNII: D733ET3F9O

✅ FDA-approved uses

Acute lymphoblastic leukemia (ALL)
Lymphoblastic lymphoma (LBL)

From the indications section of the FDA label (version of Jul 1, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06738368	Phase 2	B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	Suspended	JAZZ

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

T Acute Lymphoblastic Leukemia

More from Jazz Pharms

Calcium, Magnesium, Potassium, And Sodium Oxybates FDA approved Daunorubicin And Cytarabine Liposome FDA approved Defibrotide FDA approved Lurbinectedin FDA approved Zanidatamab FDA approved CBD-OS Phase 3 Flezurafenib Phase 1 JZP269 Phase 1 JZP926 Phase 2/3 Nabiximols Phase 2 ONC206 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the JAZZ page.

Follow JAZZ, the company behind Asparaginase Erwinia chrysanthemi

See JAZZ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

JAZZ catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z